Noriko Akiyama

Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, phase III EMIT study

Atsunori Kashiwagi, Noriko Akiyama, Takanori Shiga et al. · Diabetology International · 2014 · 59 citations

Medicine, Pharmacology, Pharmacotherapy +11

Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study)

Atsunori Kashiwagi, Takanori Shiga, Noriko Akiyama et al. · Diabetology International · 2014 · 53 citations

Medicine, Pharmacology, Pharmacotherapy +14

Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study

Takeshi Kadokura, Noriko Akiyama, Atsunori Kashiwagi et al. · Diabetes Research and Clinical Practice · 2014 · 35 citations

Medicine, Pharmacokinetics, Pharmacology +12

Pure psychiatric presentation of the Lewy body disease is depression—an analysis of 60 cases verified with myocardial meta‐iodobenzylguanidine study

Katsuji Kobayashi, Hiroyuki Nakano, Noriko Akiyama et al. · International Journal of Geriatric Psychiatry · 2014 · 16 citations · Full text

Medicine, Neurology, Psychiatry +17

Detection of Lewy body disease in patients with late‐onset depression, anxiety and psychotic disorder with myocardial meta‐iodobenzylguanidine scintigraphy

Katsuji Kobayashi, Hisashi Sumiya, Hiroyuki Nakano et al. · International Journal of Geriatric Psychiatry · 2009 · 16 citations

Medicine, Neurology, Nuclear Medicine +17